Last reviewed · How we verify
Ridaforolimus 100 mg
At a glance
| Generic name | Ridaforolimus 100 mg |
|---|---|
| Also known as | AP23573, MK-8669, deforolimus (until May 2009) |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Blood magnesium decreased
- Lymphopenia
- Nausea
- Haematuria
- Cough
- Leukopenia
- Neutropenia
- Thrombocytopenia
- Abdominal pain
- Ascites
- Constipation
- Diarrhoea
Key clinical trials
- A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037) (PHASE1)
- Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ridaforolimus 100 mg CI brief — competitive landscape report
- Ridaforolimus 100 mg updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI